Phase II study of alisertib, a selective Aurora A kinase inhibitor, in relapsed and refractory aggressive B- and T-cell non-Hodgkin lymphomas. [electronic resource]
Producer: 20140228Description: 44-50 p. digitalISSN:- 1527-7755
- Adult
- Aged
- Antineoplastic Agents -- administration & dosage
- Aurora Kinase A -- antagonists & inhibitors
- Azepines -- administration & dosage
- Burkitt Lymphoma -- drug therapy
- Drug Administration Schedule
- Female
- Humans
- Lymphoma, Follicular -- drug therapy
- Lymphoma, Large B-Cell, Diffuse -- drug therapy
- Lymphoma, Mantle-Cell -- drug therapy
- Lymphoma, T-Cell -- drug therapy
- Male
- Middle Aged
- Molecular Targeted Therapy -- methods
- Protein Kinase Inhibitors -- administration & dosage
- Pyrimidines -- administration & dosage
- Recurrence
- Treatment Outcome
No physical items for this record
Publication Type: Clinical Trial, Phase II; Journal Article; Research Support, N.I.H., Extramural
There are no comments on this title.
Log in to your account to post a comment.